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Summary  Malaria  in  children  is  still  an  important  public  health  problem  in  endemic
areas  of  South-East  Asia  and  Latin  America.  Certain  forms  of  the  disease,  such  asPlasmodium  vivax;
Pediatrics;
Plasmodium  vivax  severe  malaria,  are  still  neglected.  This  descriptive  study  assessed
the  frequency  of  severe  and  benign  P.  vivax  infection  in  Emberá  children  (<14  years
of  age)  from  an  endemic  municipality  in  Colombia  in  2013,  using  the  WHO  criteria.Epidemiology;Colombia
During  2013,  270  Emberá  children  presented  349  episodes  of  malaria.  From  them,
22  (8.1%)  presented  at  least  one  of  the  criteria  for  severe  malaria.  Some  patients
with  P.  vivax  presented  with  severe  malaria  (severe  anemia,  renal  dysfunction,
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Severe  and  benign  P.  vivax  malaria  in  Emberá  (Amerind
respiratory  distress  and  seizu
than  those  with  monoinfectio
are  available  about  severe  P.
ethnic  groups.  Mixed  infectio
At  the  same  time,  detailed  a
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espite  signiﬁcant  reductions  made  during  the  last
ecade in  the  incidence  of  malaria  in  different
egions of  the  world,  this  parasitic  disease  is  esti-
ated  to  kill  660,000—1,240,000  people  annually,
ith children  under  ﬁve  years  of  age  representing
85% of  malaria-related  deaths  [1—4]. In  the  spe-
iﬁc case  of  the  Americas,  over  the  past  decade,  the
umber of  conﬁrmed  malaria  cases  reported  in  the
egion decreased  by  almost  58%,  from  1.1  million
n 2000  to  469,000  in  2012  [1—3].  The  reduction  in
hildren  under  ﬁve  years  of  age  was  48%  [1—3].  The
alaria  mortality  is  projected  to  decrease  by  52%  in
ll of  the  age  groups  and  by  60%  in  children  younger
han 5 years  of  age  by  2015  [1—4].  This  reduction
epresents substantial  progress  toward  the  World
ealth  Assembly’s  target  of  reducing  the  malarial
urden by  75%  by  2015  [1—4].
This change  in  pattern  in  the  Americas  was
bserved in  all  of  the  endemic  countries,  with  the
xception  of  Venezuela,  Haiti  and  Guyana  [1,2]. In
enezuela, which  is  a  country  with  a  Human  Devel-
pment  Index  (HDI)  of  0.748  and  gross  national
ncome per  head  of  US$11,475,  the  malaria  inci-
ence increased  between  2000  and  2012.  A  similar
ncrease  in  incidence  was  observed  in  Guyana  and
aiti, but  both  of  these  countries  have  a  much
ower HDI  than  Venezuela,  and  a  devastating  earth-
uake hit  Haiti  during  that  period  [2].
In Colombia,  although  there  has  been  a  sig-
iﬁcant reduction  also,  speciﬁcally,  from  125,262
ases in  2007  to  60,179  in  2012  [1,5,6],  there  are
any endemic  areas  that  have  high  annual  parasitic
ndexes  (API)  (>50  cases/1000  pop.)  [7],  especially
n the  western  paciﬁc  coast  area,  where  there
re 32  departments  of  the  country;  Chocó  has  the
ighest  number  of  cases  and  incidences  [5,6].  In
olombia,  approximately  12  million  people  are  esti-
ated to  be  at  some  risk  for  malaria.  Plasmodium
alciparum is  responsible  for  <20%  of  the  malaria
ases overall,  although  the  proportion  is higher  in
ome departments  of  the  country  [1,5,6].
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re).  Mixed  malaria  cases  presented  more  complications
n  (OR  =  5.535;  95%CI  1.81—16.9).  In  Colombia,  few  data
 vivax  malaria  in  children,  especially  in  the  Amerindian
ns  were  associated  with  increased  risk  of  severe  malaria.
nd  prospective  studies  are  needed  to  measure  the  real
ia,  as  was  evidenced  in  this  paper.
ziz  University  for  Health  Sciences.  Published  by  Elsevier
Departments  in  Colombia  are  grouped  by
egions, and  one  of them,  which  is  located  in  the
ndean area,  is  the  Coffee-Triangle.  This  area  is
 topographical  region  that  includes  three  depart-
ents  (Caldas,  Quindío  and  Risaralda)  with  53
unicipalities  and  a total  population  of  2,484,345
or the  year  2013.  In  this  region,  one  of  the  munic-
palities,  Pueblo  Rico  (Fig.  1), reported  43.7%  of
he malaria  cases  between  2007  and  2011  (2877
f 6582),  with  59.5  cases/1000  pop.  in  2009  (the
ighest  incidence  in  this  53-municipalities  region)
7].
These  less  developed  municipalities  included
rban areas  above  1560  m.a.s.l.  and  rural  below
hat altitude,  with  a  population  of  12,966  inhabi-
ants in  2013  [8,9]. This  population  includes  three
thnic groups:  mestizo  (54%),  afro-colombians
14%) and  Amerindians  (Emberá)  (32%);  the  last  of
hich is  considered  to  be  a high  biological  and
ehavioral malaria-risk  group  in  the  area  [7].
The urban  area  of  this  municipality  has  the
nly hospital  in  the  area,  Hospital  San  Rafael,
hich is  responsible  to  attend  to  the  population
hat lives  in  Pueblo  Rico,  including  patients  with
alaria,  who,  as  occurs  in  Colombia  and  other
ountries, are  freely  attended  to  from  diagnos-
ics to  treatment,  which  is  covered  and  funded  by
he government  through  the  Malaria  Control  Pro-
ramme  [5].
Although  it  has  epidemiological  relevance,  there
s a lack  of  studies  on  malaria  in  the  municipality
Pueblo Rico)  as  well  as  in  the  department  where  it
s located  (Risaralda)  [7]. Thus,  our  research  groups
ere interested  on  developing  studies  to  under-
tand malaria  epidemiology  in  risk  groups  as  well  as
linical and  therapeutics  issues  in  this  area.  In  this
tudy, our  aim  is  to  assess  the  frequency  of  severe
nd benign  infection  due  to  Plasmodium  vivax,
he predominant  etiological  species  in  Pueblo  Rico
nd Colombia,  in  Emberá  children  (under  15  years
f age)  from  the  Pueblo  Rico  municipality,  Risar-
lda, Western  Colombia  (Fig.  1), during  the  year
013.
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Methods
This  research  was  a  descriptive,  cross-sectional
study in  which  the  discharge  records  of  the  Emberá
children and  adolescents  (<14  years  of  age)  who
were admitted  at  a  primary  care  hospital  in  Pueblo
Rico  municipality  (Hospital  San  Rafael)  (Fig.  1),  Ris-
aralda (Colombia)  during  January  2013  to  December
2013,  were  examined  retrospectively.  All  of  the
acutely  sick  children  who  were  admitted  with  a
febrile illness  that  was  conﬁrmed  as  malaria  (by
testing  the  peripheral  smears)  were  included  in
this study.  Malaria  infection  was  conﬁrmed  in  all
of the  cases  with  thick  and  thin  blood  smears,
with external  quality  control.  The  different  Plas-
modium  species  were  identiﬁed  morphologically  by
laboratory  experts  who  were  dedicated  to  inter-
preting malaria  smears  at  the  Malariology  Regional
Ofﬁces  in  Colombia.  In  addition,  all  of  the  positive
smears and  10%  of  those  considered  to  be  nega-
tive by  the  regional  laboratories  were  reevaluated
by a  third  national  malaria  reference  microscopist,
to conﬁrm  the  diagnosis  of  malaria.  However,  all
of the  children  who  were  admitted  with  a  febrile
illness but  were  negative  for  the  malaria  test  and
those who  had  other  associated  infections  such  as
enteric fever,  urinary  tract  infections  or  proven
meningitis/encephalitis,  were  excluded  from  the
study. The  children  from  the  other  departments
with a  positive  malaria  diagnosis  were  also  excluded
from the  study.  The  case  deﬁnition  of  severe
d
a
paralda  department,  Colombia,  South  America.
alaria  was  made  according  to  the  2014  WHO
riteria for  P.  falciparum  and  P.  vivax  [10]  (the
resence  of  one  or  more  of  the  following  clini-
al or  laboratory  features:  impaired  consciousness,
espiratory distress  [acidotic  breathing],  multiple
onvulsions,  prostration,  shock,  pulmonary  edema
radiological],  abnormal  bleeding,  jaundice,  severe
nemia, hypoglycemia,  acidosis,  hyperlactatemia,
enal impairment)  [10].
The test  results  on  malaria  for  the  study  period
ere collected  as  well  as  the  case  sheets  and  dis-
harge summaries  of  the  cases.  The  case  sheets  and
ischarge summary  sheets  were  examined  in  detail,
o identify  the  clinical  manifestations  and  labora-
ory ﬁndings  of  the  associated  cases.  The  study  was
pproved  by  the  institutional  committee  as  well
s by  the  Committee  of  Bioethics  of  the  Univer-
idad Tecnológica  de  Pereira,  Pereira,  Risaralda,
olombia.
Data regarding  the  patients’  age,  sex,  clinical
resentation, time  length  for  symptoms,  investi-
ations,  reappearance  (new  episode  in  a patient
ho suffered  malaria  during  the  same  year)  and
utcome  were  recorded.  Patients  were  categorized
nto severe  and  non-severe  groups  based  on  WHO
uidelines for  the  classiﬁcation  of  severe  malaria.
eappearance  was  deﬁned  as  a patient  who  pre-
ented with  symptoms  and  conﬁrmed  malaria  28
ays after  treatment.  Relapse  deﬁnition  cannot  be
pplied for  P.  vivax  malaria  in  this  setting  given  that
atients reside  in  an  endemic  zone.
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All  of  the  data  were  recorded  on  a  predesigned
orm; the  results  were  tabulated  and  analyzed  sta-
istically  by  SPSS  statistical  software  (version  22).
he paired  t-test,  independent  sample  t-test  and
epeated  measures  analysis  of  variance  were  used
or the  analysis  as  well  as  the  chi-square  test  for
ategorical  variables;  2-sided  p-values  are  reported
t the  0.05  signiﬁcance  level.  The  reappearance
imes (the  time  between  the  ﬁrst  diagnosis  and  sub-
equent diagnosis)  of  P.  vivax  were  calculated  using
urvival analysis.
esults
uring  the  study  period,  270  Emberá  children  pre-
ented  349  episodes  of  malaria.  Out  of  this  total,
0.7% (n  =  56)  of  the  patients  presented  more  than
ne episode  of  malaria  during  the  year,  which
ums to  135  additional  episodes.  From  the  total
umber of  children  with  malaria,  14.1%  (n  =  38)  pre-
ented two  episodes,  4.8%  (n  =  13)  three  episodes
nd 1.85%  (n  = 5)  four  episodes  during  the  same
ear. The  median  number  of  episodes  per  patient
er year  was  1.0  (interquartile  range  [IQR]  1—1).
mong  those  reappearance  cases,  40.7%  were  less
han 2 years  of  age.
The  age  of  the  subjects  ranged  from  6  days  to
3.8 years,  with  a  median  of  2.64  years  of  age  (IQR
.29—5.08)  (73.3%  were  <5  years  of  age)  (Table  1).
ne case  occurred  in  a  newborn  of  6  days  (con-
enital malaria)  and  one  case  in  a  neonate  of  24
ays (neonatal  malaria).  The  etiological  agent  of
hese cases  corresponded  to  P.  vivax  in  89.7%  of
he cases  (Table  1).  All  of  the  patients  came  from
he rural  areas  of  the  municipality,  and  all  of  them
ere included  in  the  government-subsidized  health
nsurance.
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Table  1  Demographic  and  clinical  features  of  Emberá  chil
Variables  (n
Demography
Age  (year-old,  median,  IQR)  2.
Gender  (female:male,  %)  12
Clinical
Symptoms  length  (days,  median,  IQR)  3.
Patients  hospitalized  22
Reappearances  13
Median  number  of  episodes/patient/year  1.
Etiology
P.  vivax  31
Mixed  (P.  vivax/P.  falciparum) 19
P.  falciparum  17ian)  children  and  adolescents  175
Once  diagnosed,  all  of  the  patients  were
reated with  chloroquine,  primaquine  (P.  vivax
ases)  and  artemether-lumefantrine  (P.  falcipa-
um with  or  without  P.  vivax  coinfection).  During
he study  period,  no  malaria-related  deaths  were
eported  at  the  hospital  and  none  in  Risaralda
epartment.
All of  the  patients  presented  fever  (100%).  From
he total,  22  patients  (8.1%)  presented  at  least
ne of  the  WHO  criteria  for  severe  malaria  and,
hen, were  hospitalized  (Table  2). The  hospitaliza-
ion rate  was  signiﬁcantly  higher  in  mixed  infections
26.3%)  than  in  monoinfections  (either  due  to  P.
ivax or  P.  falciparum) (6.1%)  (crude  OR  =  5.535;
5%CI 1.81—16.9).  Three  patients  were  hospitalized
wo times  (6  episodes,  5 due  to  P.  vivax  and  one
ue to  P. vivax/P.  falciparum). Among  them,  one
atient  (7  months)  presented  with  severe  anemia
nd renal  dysfunction  (due  to  P.  vivax  infection).
mong the  hospitalization  episodes,  32%  presented
ith  respiratory  distress  (6  due  to  P.  vivax  and  2
ue to  P.  vivax/P.  falciparum). Three  hospitalized
atients presented  hepatosplenomegaly  (12%);  two
ere due  to  P.  vivax/P.  falciparum, and  one  was
ue to  P.  vivax.  One  patient  who  was  hospital-
zed with  P. vivax  malaria  presented  with  seizure
4%). Due  to  these  complications  (severe  anemia  in
wo cases,  respiratory  distress  in  two  cases,  seizure
nd jaundice  with  one  case  in  each),  six  patients
ere referred  to  a tertiary  hospital  in  Pereira  (cap-
tal city  of  Risaralda  department).  No  deaths  were
eported.
Median  hemoglobin  (Hb)  was  10.0  g/dL  (IQR:
.3—11.2 g/dL,  range  4.6—12.3,  n =  58).  In  P.  vivax
edian,  Hb  was  10.0  g/dL  (IQR  8.3—11.3  g/dL,
ange 4.6—12.3,  n  =  51).  In  P.  vivax/P.  falciparum,
he median  Hb  was  8.7  g/dL  (IQR:  7.1—10  g/dL,
ange 7.0—10,  n  =  4).  In  P.  falciparum, the  median
dren  with  malaria,  Pueblo  Rico,  Colombia,  2013.
 =  270  children/349  episodes)  %
64  (1.29—5.08)
9:141  47.8:52.2
0  (2.0—6.0)
 8.1
5  38.7
0
3  89.7
 5.4
 4.9
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Table  2  Association  between  demographic  and  clinical  variables  regard  hospitalization  among  those  Emberá
children  with  malaria,  Pueblo  Rico,  Colombia,  2013.
Variables  (n  =  22  children/25  hospitalizations)  %
Demography
Age  (year-old,  median,  IQR)  0.98  (0.53—2.29)
Gender  (female:male,  %)  13/9  59.1/40.9
Clinical
Hospitalization  length  (days,  median,  IQR) 2.0  (1.0—3.0)
Etiology
P.  vivax  (n  =  313) 19 6.1
Mixed  (P.  vivax/P.  falciparum) (n  =  19) 5 26.3
P.  falciparum  (n  =  17)  1  5.9
Complications  (n  =  22  children/25  hospitalizations)  %  P.  vivax  Mixeda
Respiratory  distress  8  32.0  6  2
Hepatosplenomegaly  3  12.0  1  2
Severe  anemia  (<5  g/dL)  3  12.0  2  1
Jaundice  2  8.0  2  0
Seizure  1  4.0  1  0
a
D
M
l
A
A
t
h
t
G
a
i
c
r
e
o
C
i
w
v
i
w
b
c
o
t
i
mMixed (P. vivax/P. falciparum).
Hb  was  10.6  g/dL  (range  10.0—11.6  g/dL)  (n  = 3).
From all  of  these  patients,  5.2%  (3/58)  presented
with severe  anemia  (<5  g/dL),  which  corresponds  to
two due  to  P.  vivax  and  one  due  to  P.  vivax/P.  falcip-
arum.  No  severe  anemia  was  observed  in  patients
with P.  falciparum.
No cases  of  thrombocytopenia  were  recorded.
The median  platelet  count  was  207,900
(IQR 185,850—245,700  cells/L;  range:  153,300—
333,900 cells/L).  No  leucopenia  cases  were
recorded. The  median  white  blood  cell  count
was 11,250  (IQR  8450—12,600  cells/L;  range:
4400—17,600 cells/L).
Geometric  mean  parasitemia  was  4858
parasites/L (95%CI  4180—5646)  in  those  with
P. vivax;  4777  parasites/L (95%IC  2873—7943)  in
those with  P.  falciparum; and  7604  parasites/L in
those with  mixed  infections  (95%CI  4195—13,783).
Parasitemia  was  signiﬁcantly  associated  with
hemoglobin  levels  in  these  children  with  malaria
(r2 =  0.9593;  p  <  0.0001)  (Fig.  2).
The  mean  time  for  the  malaria  ﬁrst  reap-
pearance among  those  who  presented  with  more
than one  episode  in  a  year  was  75.9  ±  59.4  days
(range: 12.8—291.9),  while  the  mean  time  to
a second  reappearance  was  128.8  ±  46.4  days
(range: 52.3—209.1),  and  among  those  with  three
episodes  (n  =  6),  it  was  140.1  ±  54.9  days  (range:
87.8—209.1). During  the  ﬁrst  100  days  of  reappear-
ance, 83.3%  of  the  cases  occurred,  and  between
days 100  and  200,  68%  for  the  second  episode
(Fig.  3).
[
miscussion
alaria  is  still  a  signiﬁcant  public  health  prob-
em in  tropical  countries  in  Africa,  Asia  and  Latin
merica  [2—4,11,12]. In  the  speciﬁc  case  of  Latin
merica,  signiﬁcant  achievements  in  the  reduc-
ion of  the  burden  and  incidence  of  the  disease
ave been  reached  during  the  last  decade  in  all  of
he countries  of  this  region,  except  for  Venezuela,
uyana and  Haiti  [2—4]. Although  this  signiﬁcant
dvance involves  reductions  of  more  than  50%
n all  of  the  age  groups  and  close  to  60%  in
hildren younger  than  ﬁve  years,  malaria  still  rep-
esents a signiﬁcant  burden  in  this  age  group,
specially in  rural  and  more  underdeveloped  areas
f such  countries,  as  occurs  in  certain  areas  of
olombia  [7].
In  South  East  Asia  and  Latin  America,  there
s a  common  pattern  of  malaria  etiology,  in
hich >80%  of  the  cases  are  due  to  Plasmodium
ivax. The  same  pattern  occurs  in  Colombia  and
n most  of  its  departments,  including  Risaralda,
here our  study  was  performed  [7]. Tropical  areas
elow 1500  m.a.s.l.  in  the  country  are  ecologi-
ally suitable  for  the  presence  of  vector  species
f Anopheles  [13]. In  addition,  the  social  condi-
ions, especially  domestic  mobility,  represent  today
mportant  issues  for  clinical  diagnosis  and  treat-
ent of  malaria  in  Colombia,  as  in  other  countries14], especially  in  children  [15].
The  clinical  proﬁle  that  is  exhibited  in
alaria between  adults  and  children  tends  to  be
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Figure  2  Relationship  (modeled  by  non-linear  regres-
sion)  between  parasitemia  and  hemoglobinemia  in
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Figure  3  (A)  Time  to  ﬁrst  reappearance  among
children  with  malaria,  Pueblo  Rico,  Colombia,  2013
(Kaplan—Meier  survival  analysis).  (B)  Time  to  second
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Nevertheless, from  these  16  patients,  only  2 of
them were  less  than  15  years  of  age  [22].  Thus,  ourmberá  children  with  malaria.
ifferent,  especially  in  complicated  cases  [16].
n both  settings,  the  complicated  and  severe
ases were  traditionally  related  to  P.  falciparum.
owever, in  the  last  decade,  a  growing  number
f studies  in  Asia  and  the  Americas  have  showed
hat P.  vivax  can  also  produce  complicated  and
evere malaria  in  different  population  groups,
ncluding adults,  pregnant  women  and  children
17—19].  Then,  this  relatively  new  concept  should
e incorporated  into  medical  education  as  well  as
he guidelines  for  the  diagnosis  and  management  of
hildren with  malaria,  including  P.  vivax  infection
19],  but  should  also  be  addressed  in  clinical  and
pidemiological  studies.  Although  a  severe  disease
echanism  would  be  different  between  P.  vivax
nd P.  falciparum, it  is  clear  that  according  to
HO, the  research  evidence  [10—43]  is that  severe
s
seappearance  among  children  with  malaria,  Pueblo  Rico,
olombia,  2013  (Kaplan—Meier  survival  analysis).
ivax  malaria  exists  and  occurred  in  our  series  by
ulﬁlling  the  criteria  of  severe  disease  [10].
Although there  is  too  much  that  remains  to  know
bout the  pathogenesis  of  severe  vivax  disease,
enetic polymorphisms  have  been  associated  with
ncreased risk  in  patients  with  alpha-  and  beta-
halassemia  and  decreased  risk  in  those  with  G6PD
eﬁciency  and  ovalocytosis  [10].
In Colombia,  few  data  are  yet  available  about
evere P.  vivax  malaria,  in  either  adults  or  children.
s part  of a retrospective  analysis  of  the  national
rogram of  malaria,  a  study  found  that  during
he malaria  outbreak  of  2010  in  Colombia,  hepatic
OR =  1.47;  95%CI  1.05—2.06)  and  pulmonary  com-
lications  were  higher  in  those  patients  with  P.
ivax (20.9%  and  5.5%)  compared  with  those  with
. falciparum  (15.9%  and  5.0%)  [21].  However,  this
tudy was  in the  general  population,  with  30%  of
hem being  children  less  than  15  years  of  age.
oreover, the  complications  were  not  compared
t this  age  group  between  P.  vivax  and  P.  falcipa-
um [21]. Another  recent  study,  a  16  patient-case
eries, described  observed  complications  in  P.  vivax
nfection  in  three  municipalities  of  the  Paciﬁc  coast
epartments  of  Narin˜o  and  Valle  del  Cauca,  ﬁnding
yperbilirubinemia,  thrombocytopenia,  shock  and
evere anemia  to  be  among  the  most  frequent  [22].tudy is  the  ﬁrst  in  the  country  to  include  a  larger
eries of  cases  that  describe  severe  P.  vivax  malaria
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in  children.  Furthermore,  this  study  assessed  chil-
dren from  one  of  the  Amerindian  ethnic  groups  that
is present  in  Colombia,  the  Emberá.  Among  this  eth-
nic group,  there  is  a  lack  of  studies  of  malaria  [23],
even though  they  are  a  large  group  (50,000  people
living  in  Colombia)  and  present  in  malaria  endemic
areas at  the  departments  Antioquia,  Caldas,  Risar-
alda, Quindío  and  Valle  del  Cauca.
Plasmodium  vivax  infection  has  been  associ-
ated with  severe  and  fatal  disease  in  endemic
areas, including  Indonesia,  Papua  New  Guinea,
India, Brazil,  Venezuela,  Thailand,  Malaysia  and
Sudan [10—43].  Severe  manifestations  associated
with P.  vivax  infection  in  this  series  include  severe
anemia,  respiratory  distress  and  acute  lung  injury,
acute kidney  injury,  splenic  rupture,  metabolic
acidosis, jaundice,  multi-organ  dysfunction,  shock
and rarely  coma.  P.  vivax  also  causes  substantial
morbidity, especially  severe  anemia  and  low  birth-
weight [10—43].
Emberá  children  from  Pueblo  Rico,  Risaralda,
Colombia, presented  a  signiﬁcant  number  of
malaria  episodes  during  the  year  (1/5  presented
2 episodes  in  a  year,  and  some  presented  even  4
episodes  in  a  year),  which  indicates  a  high  trans-
mission pattern  in  the  area  and  a  need  for  more
efﬁcient vector  control  by  the  health  authorities.
Although it  is  known  that  in  Pueblo  Rico,  there  are
efﬁcient  vector  species,  such  as  Anopheles  darlingi
and A.  albimanus, among  others,  no  entomolog-
ical studies  on  malaria  have  been  published  in
this municipality  and  none  in  the  department  of
Risaralda.  Those  Anopheles  species  are  especially
transmitting P.  vivax,  which  represented  almost
90% of  the  etiology  in  this  study.  Then,  given  the
high transmission  in  the  area,  although  in  P.  vivax
malaria,  the  activation  of  latent  liver-stage  para-
sites (hypnozoites)  can  lead  to  new  blood-stage
infections (relapse);  this  aspect  cannot  be  discrim-
inated  in  this  study,  but  the  time  between  episodes
in Pueblo  Rico  can  be  as  short  as  8 weeks.
As expected,  most  of  the  affected  children
(almost 3/4)  were  those  who  were  less  than  5
years of  age,  as  was  previously  reported  between
2007 and  2009  for  the  department  of  Risaralda  [7],
including one  congenital  and  one  neonatal  case,
using the  corresponding  deﬁnitions  [24].  Then,  is
also raised  the  question  as  to  assessing  the  impact
of malaria  during  pregnancy,  which  is  also  impor-
tant in  a  P.  vivax  infection  [25],  in  this  region  of
the country,  where  no  studies  about  it  have  been
reported.In this  series,  although  the  frequency  was  low,
the number  of  mixed  malaria  cases  (due  to  P.  vivax
and P.  falciparum, 5.4%)  was  quite  high  compared
to other  studies  in  Latin  America,  which  usually
a
a
n
iD.A.  Medina-Morales  et  al.
ave  reported  less  than  2%  [7,26—28]. However,
he mixed  malaria  cases  were  those  that  most
requently presented  complications  and  required
he patient  to  be  hospitalized  in  this  study  (crude
R =  5.535;  95%CI  1.81—16.9).  Very  similar  recent
eports in  Bikaner  found  this,  northwest  India,
hich indicate  that  the  risk  of  developing  severe
alaria, multiorgan  dysfunction  and  mortality  was
igher in  patients  with  mixed  infection  in  compari-
on to  P.  falciparum  or  P.  vivax  monoinfection  [29].
n our  series,  other  variables,  such  as  sex,  geo-
raphic  origin,  health  insurance  and  monoinfection,
ere not  signiﬁcantly  associated  with  hospitaliza-
ion risk.
The  clinical  research  on  the  impact  of  mixed
nfection on  human  health  is  still  controversial,
hile some  authors  believe  it  to  be  a beneﬁcial
ituation whereas  others  consider  it  to  be  detri-
ental [29]. The  vast  difference  in  the  results
ould be  due  to  large-scale  incorrect  species  diag-
osis by  microscopy,  which  is  attributed  to  various
actors.  Previous  studies  on  severe  malaria  with
 larger  number  of  cases  have  strongly  indicated
he limitations  of  the  study  with  a note  of  con-
ern that  mixed  infections  might  have  been  largely
nderestimated  and  the  use  of  a more  sensi-
ive diagnostic  method  might  have  had  different
esults [29].  Furthermore,  as  has  been  recently
eported in  the  new  review  of  the  World  Health
rganization (WHO)  on  severe  malaria,  2014  [10],
n areas  that  have  higher  endemicity  of  both
pecies (P.  falciparum  and  P.  vivax),  mixed  infec-
ions are  associated  with  an  increased  risk  of
evere  malaria,  including  severe  anemia,  coma  and
eath [30,31].  However,  as  in  falciparum  malaria,
ost,  parasite  and  socio-geographical  factors  likely
ontribute to  the  risk  of  severe  disease  and
eath in  vivax  malaria,  as  well  as  speciﬁc  severe
anifestations [10].
Despite  this  pattern,  which  is  related  to  mixed
alaria infections,  in  this  study,  in  general,  patients
ith P.  vivax  presented  with  severe  malaria,  includ-
ng severe  anemia,  renal  dysfunction,  respiratory
istress and  seizure.  These  aspects  not  only  have
een reported  in  many  studies  elsewhere,  in  adults
32—35]  and  children  [30,36,37]  but  also  have
een included  recently  in  the  review  of  WHO  on
evere malaria  [29], where  it  was  acknowledged
hat P.  vivax  can  cause  complicated  and  severe  dis-
ase. In  the  WHO  review,  P.  vivax  severe  malaria
ncludes: severe  anemia,  acute  lung  injury  (ALI)
nd respiratory  distress,  acute  kidney  injury,  shock
nd multi-organ  dysfunction,  bacterial  co-infection
nd  bacteremia,  coma  and  other  vivax-associated
eurological  complications,  splenic  rupture  and
nfarction,  among  other  complications  [29].
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[12] de Almeida A, Rosário VE, Henriques G, Arez AP, Cravo P.
Plasmodium vivax in the Democratic Republic of East Timor:
parasite prevalence and antifolate resistance-associated
mutations. Acta Trop 2010;115(3):288—92.evere  and  benign  P.  vivax  malaria  in  Emberá  (Ame
In  this  study,  no  deaths  were  reported,  and  some
reviously common  reported  manifestations  of  P.
alciparum  and  P.  vivax  malaria,  such  as  thrombo-
ytopenia and  leucopenia  [38—40],  have  not  been
bserved  in  these  patients.  Because  this  study  is
etrospective,  we  cannot  further  assess  this  aspect,
ut it  will  be  carefully  observed  in  the  upcoming
rospective  studies  that  we  are  planning  to  perform
n the  same  populations.
With  respect  to  the  limitations  of  this  study,
ll of  the  patients  were  diagnosed  by  thick  and
hin blood  smears,  but  none  with  PCR.  However,
s has  been  clearly  stated  in  the  methods  sec-
ion, all  of  the  positive  smears  and  10%  of  those
onsidered to  be  negative  by  our  hospital  lab-
ratory were  reevaluated  by  a  regional  second
eference laboratory  in  Pereira  and  by  a third
ational malaria  reference  microscopist  in  Bogotá,
o conﬁrm  the  diagnosis  of  malaria.  Moreover,  fur-
her studies  in  Risaralda  will  include  PCR-based
iagnosis techniques  to  prospectively  study  severe
. vivax  malaria.  In  addition,  the  molecular  tech-
iques  will  allow  us  to  assess  the  parasite  burden
nd truly  determine  the  parasitemia  in  patients
ith P.  vivax  and  other  species  in  these  endemic
reas.
Implications of  these  ﬁndings,  as  well  as  impli-
ations from  other  observational  studies  on  severe
ivax malaria,  have  clear  beneﬁts  in  patient
are because  they  can  suggest  to  the  attend-
ng physicians  in  P.  vivax-endemic  zones  that
his parasite  can  produce  severe  forms;  then,
n assessment  can  be  made  of  this  evolution
nd the  clinical  alarm  signs  and  the  progression
o conditions  that  fulﬁll  the  criteria  of  severe
alaria, according  to  WHO,  which  now  includes
lso P.  vivax  severe  malaria  infection  [10].  Then,
voiding  and/or  reducing  the  risk  of  fatality  can
e accomplished  by  the  early  management  of
omplications.
However,  many  epidemiological,  clinical  and
athogenic questions  have  been  raised  regard-
ng severe  P.  vivax  malaria  [41—43], and  there
s growing  evidence  of  its  importance,  including
his study  for  Emberá  (Amerindian)  children  from
n endemic  area  in  Colombia.  Probably  in  other
ndemic areas  of  the  Coffee-triangle  region,  which
nclude 53  municipalities  with  variable  levels  of
alaria transmission,  mostly  due  to  P.  vivax,  this
spect would  also  be  occurring  [44].  More  detailed
nd prospective  studies  are  warranted  to  measure
he real  impact  of  P.  vivax  infection  in  children
ith severe  malaria  as  well  as  to  reduce  its  impact
s the  residual  burden  of  malaria  in  Southeast
sia and  Latin  America  countries  [37], such  as
olombia.ian)  children  and  adolescents  179
unding
o  funding  sources.
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